248602-44-0

Basic information

• Product Name: DI-FMOC-3,5-DIAMINOBENZOIC ACID
• Synonyms: DI-FMOC-3,5-DIAMINOBENZOIC ACID
• CAS NO: 248602-44-0
• Molecular Formula: C₃₇H₂₈N₂O₆
• Molecular Weight: 596.63
• Mol File: 248602-44-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: DI-FMOC-3,5-DIAMINOBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: DI-FMOC-3,5-DIAMINOBENZOIC ACID(248602-44-0)
• EPA Substance Registry System: DI-FMOC-3,5-DIAMINOBENZOIC ACID(248602-44-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 248602-44-0(Hazardous Substances Data)

Upstream product

• 535-87-5 3.5-diaminobenzoic acid 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 

Relevant articles and documents

Modular Design of Membrane-Active Antibiotics: From Macromolecular Antimicrobials to Small Scorpionlike Peptidomimetics

Infections caused by multidrug-resistant bacteria have emerged in recent decades, leading to escalating interest in host defense peptides (HDPs) to reverse this dangerous trend. Inspired by the modular design in bioengineering, herein we report a new class of small amphiphilic scorpionlike peptidomimetics based on this strategy. These HDP mimics show potent antimicrobial activity against both Gram-positive and Gram-negative bacteria without drug resistance but with a high therapeutic index. The membrane-compromising action mode was suggested to be their potential bactericidal mechanism. Pharmacodynamic experiments were conducted using a murine abscess model of methicillin-resistantStaphylococcus aureus(MRSA) infections. The lead compound 12 showed impressive in vivo therapeutic efficacy with ～99.998% (4.7log) reduction in skin MRSA burden, a significantly higher bactericidal efficiency than ciprofloxacin, and good biocompatibility. These results highlight the potential of these HDP mimics as novel antibiotic therapeutics.

Selective catalysis with peptide dendrimers

Peptide dendrimers incorporating 3,5-diaminobenzoic acid 1 as a branching unit (B) were prepared by solid-phase synthesis of ((Ac-A3) 2B-A2)2B-Cys-A1-NH2 followed by disulfide bridge formation. Twenty-one homo- and heterodimeric dendrimers were obtained by permutations of aspartate, histidine, and serine at positions A1, A2, and A3. Two dendrimers catalyzed the hydrolysis of 7-hydroxy-N-methyl-quinolinium esters (2-5), and two other dendrimers catalyzed the hydrolysis of 8-hydroxy-pyrene-1,3,6- trisulfonate esters (10-12). Enzyme-like kinetics was observed in aqueous buffer pH 6.0 with multiple turnover, substrate binding (KM = 0.1 -0.5 mM), rate acceleration (kcat/kuncat > 103), and chiral discrimination (E = 2.8 for 2-phenylpropionate ester 5). The role of individual amino acids in catalysis was investigated by amino acid exchanges, highlighting the key role of histidine as a catalytic residue, and the importance of electrostatic and hydrophobic interactions in modulating substrate binding. These experiments demonstrate for the first time selective catalysis in peptide dendrimers.

Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents

Novel membrane-forming amphiphilic lipopeptides comprising one or more peptide moieties containing 2-50 aminoacyl residues and one or more hydrocarbon chains containing 5-50 carbon atoms. Such lipopeptides may be used in the formation of stabilized gas microbubble dispersions suitable for use as diagnostic and/or therapeutic agents, for example as ultrasound contrast agents.